Table 1. Main characteristics of all the studies included in the meta-analysis.
| Author | Year | Region | Single or multicenter | No. of patients | mean/median age(ys) | WHO stage | expression detection method | outcomes | Follow up period (years or months or day) | Survival analysis | Adjusted variables | Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Slamon et al. [6] | 1989 | USA | single | 120 | NR | NR | IHC/South | OS | median 75.4 months | Univariate | _ | _ |
| Berchuck et al. [7] | 1990 | USA | single | 73 | NR | III-IV | IHC | OS | NR | Univariate | _ | _ |
| Rubin et al. [19] | 1993 | USA | single | 105 | mean 59(33-81) | III-IV | IHC | OS | median 34 months | multivariate | Stage, grade, residual tumor, histologicaltype, Residual tumor | Platinum-based |
| Scambia et al. [20] | 1993 | Italy | single | 94 | median 57(14-83) | III-IV | IHC | PFS | median 24 months | Univariate | Age, Stage, grade, Ascites, histological type, Surgical debulking, Response to chemotherapy | Platinum-based |
| Singleton et al. [21] | 1994 | USA | single | 56 | NR | I-IV | IHC | OS | NR | Univariate | stage, histopathologic subtype, grade | Platinum-based |
| Rubin et al. [22] | 1994 | USA | single | 40 | mean 53(26-77) | I-II | IHC | PFS OS | mean 32 months | Univariate | Stage, histological type, grade | _ |
| van Dam et al. [23] | 1994 | Norwegian | single | 80 | NR | I-IV | IHC | OS | NR | multivariate | Age, stage, histopathologicsubtype, grade, residualdisease, c-myc, c-ras, EGFR | Platinum-based |
| Felip et al. [24] | 1995 | Spain | single | 72 | Mean 55 (19-74) | I-IV | IHC | OS | median 50 weeks | multivariate | Age, Stage, histological type, Residual tumor, Chemotherapy | Ca.C |
| Fajac et al. [25] | 1995 | France | single | 65 | mean 52 | I-IV | Southern Blot | OS | median 71 months | univariate and multivariate | Ag, Stage, grade, histological type, Residual tumor | Platinum-based |
| Medl et al. [26] | 1995 | Austria | Multicenter | 196 | median 59.6(15-88) | I-IV | PCR | OS | mean 59 months | Univariate | Stage, grade, Residual tumor, Ascites, INT-2, ER | Platinum-based |
| Kaufmann et al. [27] | 1995 | Germany | single | 77 | median 63 (33-83) | I-IV | immunoassay | OS | median 19 months | multivariate | age, stage, residual tumor, Ca125, Chemotherapy | Platinum-based |
| van der Zee et al. [28] | 1995 | Netherlands. | single | 89 | mean 50 | I-IV | IHC | PFS | NR | multivariate | Age, Stage, grade, Ascites, histological type, P53, Chemotherapy | Platinum-based |
| Tanner et al. [29] | 1996 | Germany | single | 79 | NR | I-IV | S1 Nuclease Assay | OS | NR | multivariate | FIGO stage, histopathologic subtype, grade | P.C/Ca.C |
| Beckmann et al. [30] | 1996 | Germany. | single | 79 | mean52 (34-80) | I-IV | PCR | PFS OS | median 42 months | multivariate | age, stage of disease, grade, c-myc | Ca.C |
| Meden et al. [9] | 1998 | Germany | single | 208 | mean 60 | I-IV | IHC | OS | median 24 months | Univariate | Age, Stage, grade, histological type, chemotherapy | P.C/Ca.C |
| Hengstler et al. [3] | 1999 | Germany | single | 77 | NR | I-IV | S1 Nuclease Assay | OS | NR | multivariate | Age, FIGO stage, histopathologic subtype, residual disease, chemotherapy, grade, | Platinum-based |
| Wang ZR et al. [32] | 1999 | USA | single | 40 | median 61 (35-83) | II–IV | FISH | OS | maximum 56 months. | multivariate | Age, Stage, grade, histological type, c-myc | _ |
| Davidson et al. [10] | 2000 | Israel | single | 45 | median 56 (30–84) | III–IV | IHC | OS | Mean 70 months | multivariate | Age, histological type, EGFR, E-cadherin, Y-Catenin | _ |
| Seki et al. [33] | 2000 | Japan | single | 48 | NR | I-IV | PCR | OS | maximum 87months. | NR | Age, Stage, grade, histological type, tumor size, Ascites, CA-125, residual disease | _ |
| Frutuoso et al. [34] | 2001 | Portuguesa | single | 81 | mean 55.4 ± 15 | I-III | IHC | OS | NR | Univariate | Age, Stage, grade, Residual tumor, histological type, P53 | _ |
| Skirnisdottir et al. [35] | 2001 | Sweden | single | 106 | mean 60 | IA-IIC | IHC | OS | median87 | Univariate | mean age, FIGO stage and histopathologic subtype, grade, EGFR | Platinum-based |
| Li et al. [36] | 2002 | china | single | 84 | median 49 | I-IV | IHC | OS | median 32.8 months | Univariate | age, FIGO stage and histopathologic subtype, grade, P53, | _ |
| Hogdall et al. [37] | 2003 | Danish | Multicenter | 181 | median 60 | I-IV | IHC | 0s | NR | multivariate | _ | _ |
| Tomic et al. [38] | 2003 | Croatia | single | 80 | median 59 (34-79) | I-IV | IHC | OS | median 21month | multivariate | age, stage, grade, p53, nm23, Vascular invasion | _ |
| Camilleri-Broet et al. [39] | 2004 | Europe | Multicenter | 117 | median 59 (18-70) | III-IV | IHC | OS PFS | median of 68 months | multivariate | age, stage, Ascites, grade, Tumor type, P53, BCL-2, receptors | P.E.C |
| Nielsen et al. [40] | 2004 | Denmark | Multicenter | 783 | median 58(13-91) | I-IV | IHC | OS | median 17.8 years | multivariate | age, stage, grade, histological type, P53, EGFR | P.A.C/Ca.C |
| Riener et al. [41] | 2004 | Germany | Multicenter | 361 | median 57.6 | IIB–IV | IHC | OS, PFS | median 49.1 months | Univariate | Stage, grade, histological type, residual tumor, lymph node metastasis | Platinum-based |
| Tanabe et al. [42] | 2004 | Japan | Multicenter | 90 | NR | I-IV | IHC | OS | NR | Univariate | Stage, histological type, lymph node metasta-sis | _ |
| Elie et al. [11] | 2004 | France | multicentre | 93 | Median 58 | III-IV | IHC | PFS OS | median 69 months | multivariate | Age, Stage, grade, Ascites, histological type, Residual tumour | Platinum-based |
| Chan et al. [43] | 2004 | USA | multicentre | 46 | mean 41 years | III–IV | IHC | OS | median 37 months | multivariate | Age, Stage, grade, histological type | Platinum-based |
| Lee et al. [44] | 2005 | British | single | 103 | mean 58(35-82) | III-IV | IHC/FISH | PFS | NR | Univariate | _ | P.T |
| Verri et al. [45] | 2005 | Italy | single | 194 | Median 57 (25–90) | I-IV | IHC | OS PFS | median 45 months | multivariate | Age, stage, grade, histologicaltype, residual tumor | Platinum-based |
| Wang et al. [46] | 2005 | Norway | single | 118 | median 60(38-81) | II–IV | IHC | PFS | Median 72 months | multivariate | Age, Stage, grade, histological type, residual disease, ER | Platinum-based |
| Mayr et al. [12] | 2006 | Germany | single | 163 | NR | I-IV | IHC/FISH | OS | NR | Univariate | Age, Stage, histological type | _ |
| Surowiak et al. [47] | 2006 | Poland | single | 43 | mean 51.0 | I-III | IHC | PFS OS | Median 24.6 months | multivariate | Age, Stage, grade, histological type, Clinical response, CA-15, type of chemotherapy | P.C/A.C.C |
| Castellvi et al. [48] | 2006 | Spain | single | 75 | mean 55(20-87) | I-IV | IHC | OS | Median 31months | multivariate | Age, stage, grade, histologicaltype, residual tumor | _ |
| Brozek et al. [49] | 2006 | Poland | single | 53 | NR | I-IV | FISH: | OS | NR | Univariate | Age, Stage, grade, histological type, CA-125, chemotherapy | Platinum-based |
| Steffensen et al. [50] | 2007 | Danish | single | 160 | median 54.5 (29–70) | IIB–IV | IHC/FISH | OS | 》10 years | multivariate | Age, stage, grade, histological type, residual tumor, COX2 expression | _ |
| Sueblinvong et al. [51] | 2007 | Thailand | Multicenter | 74 | mean 46.31(24–67) | I-II | IHC/FISH | OS, PFS | median 46 months | multivariate | Age, Stage, grade, Ascites, histological type, capsular rupture, capsular adherence | _ |
| Tuefferd et al. [52] | 2007 | France | Multicenter | 320 | median 58 (25–77) | I-IV | IHC/FISH | OS PFS | NR | multivariate | Age, Stage, grade, Residual tumor, Ascites, histological type, and performance status | _ |
| Sasaki et al. [53] | 2007 | Japan | single | 141 | median 53(23-81) | I-IV | IHC | OS | NR | multivariate | Age, Stage, grade, histological type, residual disease, Ascites, type of chemotherapy | CAP |
| Malamou-Mitsi et al. [54] | 2007 | Greece | multicentre | 95 | mean 63 | IIc-IV | IHC | OS/PFS | Median 66 months | multivariate | Age, Stage, grade, histological type, residual disease, P53, Bcl-2, type of chemotherapy | P.C |
| Coronado Martin et al. [55] | 2007 | Spain | single | 124 | median 59.2 | I-IV | IHC | PFS OS | Median 62.3 months | multivariate | Age, Stage, grade, histological type, Cirugía óptima, P53 | _ |
| Pils et al. [56] | 2007 | Austria | single | 128 | mean58.6 (27.6–87.2 years). | I-IV | IHC | OS | Median 43.7 months | multivariate | Age, Stage, grade, histological | P.C |
| Tomsova et al. [57] | 2008 | Europe | single | 116 | median 53 ( 27–82) | I-IV | IHC | OS | Median 39 months | multivariate | , Stage, grade, histological type, type of chemotherapy | Platinum-based |
| de Graeff et al. [58] | 2008 | Netherlands | single | 232 | median 57.8 (22–90) | I-IV | immunostain | OS PFS | NR | Univariate | Age, Stage, grade, Suboptimal debulking, EGFR | Platinum-based |
| Garcia-Velasco et al. [59] | 2008 | Spain | single | 72 | median 57 (28–82) | NA | IHC | OS PFS | median 33 months | Univariate | Age, Stage, grade, Residual disease, ER, PR, P53, | P.C/P.C.C/Ca.C |
| Pfisterer et al. [60] | 2009 | Germany | multicentre | 359 | mean 65 | IIB-IV | IHC | PFS OS | median 57.5 months | multivariate | Age, Stage, grading, histological type, residual disease, tchemotherapy | Platinum-based |
| Farley et al. [61] | 2009 | USA | multicentre | 133 | median 59.5 (21.7–78.6) | III–IV | ERBB2/CEP17 | PFS OS | NR | multivariate | Age, Stage, grade, histological type, residual disease, Ascites, type of chemotherapy | Platinum-based |
| Ferrero et al. [62] | 2011 | Italy | single | 113 | median 62(25-80) | IIb–IV | IHC | OS | NR | Univariate | Age, Stage, grade, histological type, postoperative residual tumor, type of chemotherapy | Platinum-based |
| Anglesio et al. [63] | 2013 | Alberta/AOCS/Mayo/Toronto | multicenter | 189 | mean 57.8 (20–97) | I-IV | IHC/FISH/CIS | OS PFS | median 4.4 Years | multivariate | age, stage, and debulking statu, KRAS mutation status | _ |
| Chay et al. [64] | 2013 | Singapore | multicenter | 133 | median 48.3 (15.8–89.0) | I-IV | DISH, IHC | OS PFS | NR | Stage-Adjusted Analysis | Age, Stage, Ethnic group, differentiation, Lymphovascular invasion | _ |
| Demir et al. [65] | 2014 | Turkey | single | 82 | median 54 (24–80) | I-IV | IHC | OS | NR | multivariate | Age, Stage, Residual disease, Distant Metastasis | _ |
| de Toledo et al. [66] | 2014 | Brazil | single | 152 | mean 55.2 | I-IV | IHC | OS, PFS | mean 43.6 months | multivariate | Age, Menopause, BMI, Histology, Grade, Stage, Residual disease, ER, PR, AR, TNEOC expression | Platinum-based |
| Farkkila et al. [67] | 2014 | Finland | single | 80 | median 52 (19–87) | I-III | IHC | PFS | mean 16.8 years | multivariate | stage, GATA4 expression, nuclear atypia | Platinum-based |
| Cai et al. [68] | 2015 | China | single | 95 | NR | I-IV | IHC | OS | NR | multivariate | grade, histology, stage, FASN expression | _ |
A.C.C, adriamycin+cyclophosphamide+Carboplatin; Ca.C, Carboplatin+cyclophosphamide; COX2,cytochrome c oxidase subunit II; ER,estrogen receptor; EGFR, epidermal growth factor receptor; FIGO, International Federation of Gynecology and Obstetrics; FASN,fatty acid synthase; FISH, fluorescence in situ hybridization; GATA4,GATA binding protein 4; IHC, Immunohistochemistry; N, no; NR, not reported; OS, overall survival; PFS, progression-free survival; P.A.C, Cisplatin+adriamycin+cyclophosphamide; P.C, Cisplatin+cyclophosphamide; P.T, Paclitaxel and cisplatin; P53,nuclear protein 53; PR, Progesterone receptor; TNEOC, triple-negative epithelial ovarian cancer; RT-PCR reverse transcription–polymerase chain reaction; Y, yes.